Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function

Fatih Yalçin, Fatma G. Aksoy, Haldun Muderrisoglu, Irfan Sabah, Mario J. Garcia, James D. Thomas

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Hypertension is a major independent risk factor for cardiac deaths, and diastolic dysfunction is a usual finding during the course of this disease. Hypothesis: This study was designed to investigate the effects of chronic therapy with perindopril on left ventricular (LV) mass, left atrial size, diastolic function, and plasma level of atrial natriuretic peptide (ANP) in patients with hypertension. Methods: Twenty four patients who had not been previously taking any antihypertensive medication and without prior history of angina pectoris, myocardial infarction, congestive heart failure, dysrhythmias, valvular heart disease, or systemic illnesses received 4-8 mg/day of perindopril orally. Echocardiographic studies were acquired at baseline and 6 months after the initiation of therapy. Results: Systolic and diastolic blood pressure decreased from 174 ± 19.7 and 107.5 ± 7.8 mmHg to 134 ± 10.6 and 82 ± 6.7 mmHg, respectively (p < 0.001). Left ventricular mass decreased from 252.4 ± 8.3 to 205.7 ± 7.08 g and left atrial volume from 20.4 ± 5.1 to 17.6 ± 5.2 ml, respectively (p < 0.001). Transmittal Doppler early and atrial filling velocity ratio (E/A) increased from 0.69 ± 0.06 to 0.92 ± 0.05 m/s and plasma ANP level decreased from 71.9 ± 11.7 to 35.3 ± 7.8 pg/ml (p < 0.001). Reduction of LV mass correlated positively with a reduction in ANP levels (r = 0.66, p < 0.0005). Conclusions: Perindopril caused a significant reduction of LV mass, left atrial volume, and plasma ANP levels, as well as improvement in Doppler parameters of LV filling in this group of patients with hypertension.

Original languageEnglish (US)
Pages (from-to)437-441
Number of pages5
JournalClinical Cardiology
Volume23
Issue number6
StatePublished - 2000
Externally publishedYes

Fingerprint

Perindopril
Atrial Natriuretic Factor
Hypertension
Blood Pressure
Heart Valve Diseases
Plasma Volume
Angina Pectoris
Therapeutics
Antihypertensive Agents
Heart Failure
Myocardial Infarction

Keywords

  • Angiotensin-converting enzyme inhibition
  • Atrial natriuretic peptide
  • Diastolic dysfunction
  • Hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function. / Yalçin, Fatih; Aksoy, Fatma G.; Muderrisoglu, Haldun; Sabah, Irfan; Garcia, Mario J.; Thomas, James D.

In: Clinical Cardiology, Vol. 23, No. 6, 2000, p. 437-441.

Research output: Contribution to journalArticle

@article{c5a86abcbdb54054a25c94aa3079f070,
title = "Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function",
abstract = "Background: Hypertension is a major independent risk factor for cardiac deaths, and diastolic dysfunction is a usual finding during the course of this disease. Hypothesis: This study was designed to investigate the effects of chronic therapy with perindopril on left ventricular (LV) mass, left atrial size, diastolic function, and plasma level of atrial natriuretic peptide (ANP) in patients with hypertension. Methods: Twenty four patients who had not been previously taking any antihypertensive medication and without prior history of angina pectoris, myocardial infarction, congestive heart failure, dysrhythmias, valvular heart disease, or systemic illnesses received 4-8 mg/day of perindopril orally. Echocardiographic studies were acquired at baseline and 6 months after the initiation of therapy. Results: Systolic and diastolic blood pressure decreased from 174 ± 19.7 and 107.5 ± 7.8 mmHg to 134 ± 10.6 and 82 ± 6.7 mmHg, respectively (p < 0.001). Left ventricular mass decreased from 252.4 ± 8.3 to 205.7 ± 7.08 g and left atrial volume from 20.4 ± 5.1 to 17.6 ± 5.2 ml, respectively (p < 0.001). Transmittal Doppler early and atrial filling velocity ratio (E/A) increased from 0.69 ± 0.06 to 0.92 ± 0.05 m/s and plasma ANP level decreased from 71.9 ± 11.7 to 35.3 ± 7.8 pg/ml (p < 0.001). Reduction of LV mass correlated positively with a reduction in ANP levels (r = 0.66, p < 0.0005). Conclusions: Perindopril caused a significant reduction of LV mass, left atrial volume, and plasma ANP levels, as well as improvement in Doppler parameters of LV filling in this group of patients with hypertension.",
keywords = "Angiotensin-converting enzyme inhibition, Atrial natriuretic peptide, Diastolic dysfunction, Hypertension",
author = "Fatih Yal{\cc}in and Aksoy, {Fatma G.} and Haldun Muderrisoglu and Irfan Sabah and Garcia, {Mario J.} and Thomas, {James D.}",
year = "2000",
language = "English (US)",
volume = "23",
pages = "437--441",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function

AU - Yalçin, Fatih

AU - Aksoy, Fatma G.

AU - Muderrisoglu, Haldun

AU - Sabah, Irfan

AU - Garcia, Mario J.

AU - Thomas, James D.

PY - 2000

Y1 - 2000

N2 - Background: Hypertension is a major independent risk factor for cardiac deaths, and diastolic dysfunction is a usual finding during the course of this disease. Hypothesis: This study was designed to investigate the effects of chronic therapy with perindopril on left ventricular (LV) mass, left atrial size, diastolic function, and plasma level of atrial natriuretic peptide (ANP) in patients with hypertension. Methods: Twenty four patients who had not been previously taking any antihypertensive medication and without prior history of angina pectoris, myocardial infarction, congestive heart failure, dysrhythmias, valvular heart disease, or systemic illnesses received 4-8 mg/day of perindopril orally. Echocardiographic studies were acquired at baseline and 6 months after the initiation of therapy. Results: Systolic and diastolic blood pressure decreased from 174 ± 19.7 and 107.5 ± 7.8 mmHg to 134 ± 10.6 and 82 ± 6.7 mmHg, respectively (p < 0.001). Left ventricular mass decreased from 252.4 ± 8.3 to 205.7 ± 7.08 g and left atrial volume from 20.4 ± 5.1 to 17.6 ± 5.2 ml, respectively (p < 0.001). Transmittal Doppler early and atrial filling velocity ratio (E/A) increased from 0.69 ± 0.06 to 0.92 ± 0.05 m/s and plasma ANP level decreased from 71.9 ± 11.7 to 35.3 ± 7.8 pg/ml (p < 0.001). Reduction of LV mass correlated positively with a reduction in ANP levels (r = 0.66, p < 0.0005). Conclusions: Perindopril caused a significant reduction of LV mass, left atrial volume, and plasma ANP levels, as well as improvement in Doppler parameters of LV filling in this group of patients with hypertension.

AB - Background: Hypertension is a major independent risk factor for cardiac deaths, and diastolic dysfunction is a usual finding during the course of this disease. Hypothesis: This study was designed to investigate the effects of chronic therapy with perindopril on left ventricular (LV) mass, left atrial size, diastolic function, and plasma level of atrial natriuretic peptide (ANP) in patients with hypertension. Methods: Twenty four patients who had not been previously taking any antihypertensive medication and without prior history of angina pectoris, myocardial infarction, congestive heart failure, dysrhythmias, valvular heart disease, or systemic illnesses received 4-8 mg/day of perindopril orally. Echocardiographic studies were acquired at baseline and 6 months after the initiation of therapy. Results: Systolic and diastolic blood pressure decreased from 174 ± 19.7 and 107.5 ± 7.8 mmHg to 134 ± 10.6 and 82 ± 6.7 mmHg, respectively (p < 0.001). Left ventricular mass decreased from 252.4 ± 8.3 to 205.7 ± 7.08 g and left atrial volume from 20.4 ± 5.1 to 17.6 ± 5.2 ml, respectively (p < 0.001). Transmittal Doppler early and atrial filling velocity ratio (E/A) increased from 0.69 ± 0.06 to 0.92 ± 0.05 m/s and plasma ANP level decreased from 71.9 ± 11.7 to 35.3 ± 7.8 pg/ml (p < 0.001). Reduction of LV mass correlated positively with a reduction in ANP levels (r = 0.66, p < 0.0005). Conclusions: Perindopril caused a significant reduction of LV mass, left atrial volume, and plasma ANP levels, as well as improvement in Doppler parameters of LV filling in this group of patients with hypertension.

KW - Angiotensin-converting enzyme inhibition

KW - Atrial natriuretic peptide

KW - Diastolic dysfunction

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=0343674735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343674735&partnerID=8YFLogxK

M3 - Article

C2 - 10875035

AN - SCOPUS:0343674735

VL - 23

SP - 437

EP - 441

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 6

ER -